Description

 

Retatrutide by GenPep – 24 mg Pen

Description

Retatrutide by GenPep is a high-purity, research-grade formulation designed for ongoing studies in metabolic and peptide science. Each pre-filled 24 mg pen contains a measured solution of retatrutide for controlled subcutaneous administration within laboratory or investigational settings.

⚠️ For research use only. Not for human or veterinary use.

---

Product Overview

Active compound: Retatrutide (LY3437943) — 24 mg per pen
Format: Single-use, pre-filled subcutaneous pen

Suggested research model:
Once-weekly administration (investigational context only)

Mechanistic profile:
Multi-agonist peptide acting on:

• GLP-1 receptors
• GIP receptors
• Glucagon receptors

These receptor systems regulate:

• appetite signaling
• energy expenditure
• insulin secretion
• metabolic flexibility

Manufacturer:
Compounded by GenPep Pharmacy, operating under GMP-aligned quality and purity standards

---

Handling & Storage

• Store refrigerated at 2 °C – 8 °C
• Do not freeze
• Protect from light and heat
• Use only within authorized research protocols
• Handle according to Good Laboratory Practices (GLP)

---

Evidence-Based Dose Levels Used in Human Trials

(Educational Context Only)

Retatrutide is investigational. Dose levels and titration strategies vary by trial protocol.

In the 48-week Phase 2 obesity study, maintenance doses evaluated included:

• 1 mg weekly
• 4 mg weekly
• 8 mg weekly
• 12 mg weekly

These were reached through gradual dose escalation to improve tolerability.

Primary reference:

Jastreboff AM et al., New England Journal of Medicine, 2023
https://pubmed.ncbi.nlm.nih.gov/37366315/

Clinical trial registry:
https://clinicaltrials.gov/study/NCT04881760

---

Incremental Dose Ladder (Research Context)

Weekly dose	Status in trials	Reference	24 mg pen coverage
1 mg	Studied	https://pubmed.ncbi.nlm.nih.gov/37366315/	24 weeks
2 mg	Escalation step	https://clinicaltrials.gov/study/NCT04881760	12 weeks
4 mg	Studied (maintenance)	https://pubmed.ncbi.nlm.nih.gov/37366315/	6 weeks
6 mg	Escalation step	https://clinicaltrials.gov/study/NCT04881760	4 weeks
8 mg	Studied (maintenance)	https://pubmed.ncbi.nlm.nih.gov/37366315/	3 weeks
9 mg	Escalation step	https://clinicaltrials.gov/study/NCT04881760	2.7 weeks
12 mg	Studied (highest maintenance dose)	https://pubmed.ncbi.nlm.nih.gov/37366315/	2 weeks

⚠️ These values describe clinical trial designs and are not dosing recommendations.

---

Clinical Dosing Data and Pen-Based Interpretation

Phase 2 Obesity Trial (48 Weeks)

The pivotal Phase 2 trial demonstrated:

• Up to ~24% mean weight reduction
• Strong dose-response relationship
• Higher doses associated with greater metabolic improvement

Reference:
https://pubmed.ncbi.nlm.nih.gov/37366315/

Clinical trial registry:
https://clinicaltrials.gov/study/NCT04881760

---

Phase 2 Type 2 Diabetes Study

Parallel metabolic trials demonstrated:

• Significant HbA1c reductions
• Improved fasting glucose
• Improved post-prandial glucose control
• Reduction in insulin resistance markers

Reference:
Coskun T et al., Cell Metabolism, 2022
https://pubmed.ncbi.nlm.nih.gov/35605025/

---

Dose Escalation Strategy

Across studies, retatrutide was not initiated at target doses.

Gradual titration was used to reduce gastrointestinal adverse effects common to incretin therapies.

This reflects receptor adaptation and tolerability management, not limitations in pharmacologic potency.

---

Pen-Based Dose Mapping (24 mg Total)

A 24 mg pen corresponds to cumulative amounts consistent with published trials:

• 2 × 12 mg doses
• 3 × 8 mg doses
• 6 × 4 mg doses
• 24 × 1 mg doses

This format allows laboratories to model multiple clinical trial dose arms within a standardized preparation.

⚠️ No assumptions are made regarding titration schedule, subject selection, or treatment duration.

---

Retatrutide (LY3437943): Educational Overview

Executive Summary

Retatrutide is an investigational triple-agonist incretin therapy activating:

• GLP-1 receptors
• GIP receptors
• glucagon receptors

This multi-pathway engagement affects:

• appetite regulation
• insulin signaling
• lipid metabolism
• hepatic glucose handling
• energy expenditure

References:

Coskun T et al., Cell Metabolism, 2022
https://pubmed.ncbi.nlm.nih.gov/35605025/

Jastreboff AM et al., NEJM, 2023
https://pubmed.ncbi.nlm.nih.gov/37366315/

---

Mechanism of Action

GLP-1 Receptor Activation

GLP-1 signaling:

• increases glucose-dependent insulin secretion
• slows gastric emptying
• activates satiety pathways in the brain

Reference:

Drucker DJ, Cell Metabolism, 2018
https://pubmed.ncbi.nlm.nih.gov/30270059/

---

GIP Receptor Activation

GIP signaling:

• enhances insulin secretion
• improves adipocyte insulin sensitivity
• modulates lipid metabolism

References:

Finan B et al., Nature Medicine, 2013
https://pubmed.ncbi.nlm.nih.gov/23852340/

Nauck MA et al., Diabetes Care, 2021
https://pubmed.ncbi.nlm.nih.gov/33547158/

---

Glucagon Receptor Activation

Retatrutide uniquely activates glucagon receptors.

This increases:

• hepatic fat oxidation
• energy expenditure
• triglyceride mobilization

References:

Habegger KM et al., Nature Medicine, 2010
https://pubmed.ncbi.nlm.nih.gov/20305658/

Kim T et al., Cell Metabolism, 2018
https://pubmed.ncbi.nlm.nih.gov/29514060/

---

Clinical Trial Evidence

Obesity (Phase 2)

Key outcomes:

• up to 24% body weight reduction
• majority of weight loss from fat mass

Reference:

https://pubmed.ncbi.nlm.nih.gov/37366315/

---

Type 2 Diabetes

Observed effects:

• HbA1c reduction
• improved glycemic control
• reduced insulin resistance

Reference:

https://pubmed.ncbi.nlm.nih.gov/35605025/

---

Body Composition Effects

Retatrutide appears to:

• reduce visceral adipose tissue
• reduce hepatic steatosis
• preserve lean mass when combined with resistance training

Reference:

Gastaldelli A et al., Diabetes, 2020
https://pubmed.ncbi.nlm.nih.gov/32198202/

---

Neurological Research Context

GLP-1 receptors are expressed in multiple brain regions including:

• hippocampus
• hypothalamus
• cortex

These pathways may influence:

• neuroinflammation
• neuronal energy metabolism
• cognitive signaling

Reference:

Hölscher C, Nature Reviews Neuroscience, 2014
https://pubmed.ncbi.nlm.nih.gov/24651702/

---

Cardiovascular and Renal Effects

Incretin therapies have demonstrated:

• improved endothelial function
• reduced systemic inflammation
• lower cardiovascular risk markers

Reference:

Marso SP et al., NEJM, 2016
https://pubmed.ncbi.nlm.nih.gov/27633186/

---

Safety and Tolerability

Common adverse events in trials include:

• nausea
• vomiting
• diarrhea
• constipation

These are generally dose-dependent and improve with titration.

Reference:

https://pubmed.ncbi.nlm.nih.gov/33547158/

---

Cancer Risk Evidence

Early rodent studies raised thyroid cancer concerns.

Human data has not demonstrated increased thyroid cancer incidence.

Reference:

Alves C et al., BMJ, 2012
https://pubmed.ncbi.nlm.nih.gov/22894536/

---

Final Perspective

Retatrutide represents a next-generation metabolic therapy designed to address root metabolic dysfunction rather than simply suppress appetite.

Through combined activation of GLP-1, GIP, and glucagon receptors, it influences multiple physiological systems involved in modern metabolic disease.

However, outcomes ultimately depend on integration with nutrition, physical activity, sleep, and overall metabolic health strategies.